High ability to predict the treatment outcome of peginterferon and ribavirin combination therapy based on the reduction in HCV RNA levels at 4 weeks after starting therapy and amino acid substitutions in the hepatitis C virus in patients infected with HCV genotype 1b.
Toyoda
Hidenori
H
Department of Gastroenterology, Ogaki Municipal Hospital, 4-86 Minaminokawa, Ogaki, Gifu 503-8502, Japan. hmtoyoda@spice.ocn.ne.jp
Kumada
Takashi
T
Kiriyama
Seiki
S
Tanikawa
Makoto
M
Hisanaga
Yasuhiro
Y
Kanamori
Akira
A
Tada
Toshifumi
T
Arakawa
Takahiro
T
Fujimori
Masashi
M
Niinomi
Takuro
T
Ando
Naoto
N
Yasuda
Satoshi
S
Sakai
Keisuke
K
Kimura
Jun
J